
Article
Why Weight Regain Happens After Tirzepatide Trials Stop
Randomized withdrawal trials show that weight often returns when incretin treatment stops. The harder question is whether that is personal failure, biology, or both.
Read article
Article
Randomized withdrawal trials show that weight often returns when incretin treatment stops. The harder question is whether that is personal failure, biology, or both.
Read article
Article
Skin elasticity can be measured with instruments, not just judged in the mirror. Human trials of oral collagen peptides show modest changes, but the evidence is short-term and mostly industry-funded.
Read article
Article
Large phase 3 trials show tirzepatide weight loss can be substantial while treatment continues, with regain after withdrawal. The evidence is strong for the trial populations, but menopause-specific reporting is thin.
Read article
Article
A close read of bremelanotide clinical studies in women: who was enrolled, what endpoints were measured, what improved, what did not, and why the data leave major gaps for perimenopause and menopause.
Read article
Article
Retatrutide and tirzepatide are often compared, but the evidence is not evenly mature. This review looks at what human trials actually measured, where the endpoints overlap, and where the comparison stops.
Read article
Article
Human trials of NAD+ precursors have measured blood NAD+ metabolites, skeletal-muscle signaling, and insulin sensitivity. The evidence is more interesting than simple wellness claims suggest—but thinner, and more sex-specific, than most readers are told.
Read article
Article
A practical buyer’s guide to peptide COAs, HPLC purity, mass spectrometry, batch identity, and the supplier transparency signals that matter before purchasing research peptides in Canada.
Read article